Nabriva Therapeutics (NASDAQ:NBRV) has been given a consensus rating of “Buy” by the ten ratings firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $17.29.

NBRV has been the subject of a number of research analyst reports. Cantor Fitzgerald set a $16.00 price objective on shares of Nabriva Therapeutics and gave the stock a “buy” rating in a research report on Friday, March 16th. ValuEngine cut shares of Nabriva Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Zacks Investment Research upgraded shares of Nabriva Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 4th. Bank of America initiated coverage on shares of Nabriva Therapeutics in a research report on Wednesday, March 21st. They set a “buy” rating and a $10.00 price objective for the company. Finally, Wedbush reiterated an “outperform” rating on shares of Nabriva Therapeutics in a research report on Monday, March 19th.

In related news, General Counsel Robert Crotty acquired 10,000 shares of the stock in a transaction that occurred on Wednesday, May 23rd. The stock was acquired at an average cost of $4.48 per share, for a total transaction of $44,800.00. Following the transaction, the general counsel now directly owns 10,000 shares in the company, valued at $44,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stephen W. Webster acquired 8,000 shares of the stock in a transaction that occurred on Wednesday, May 23rd. The shares were bought at an average price of $4.59 per share, with a total value of $36,720.00. Following the completion of the transaction, the director now owns 8,000 shares in the company, valued at $36,720. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 20,000 shares of company stock valued at $90,660. 2.75% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC bought a new stake in Nabriva Therapeutics during the 4th quarter worth approximately $5,188,000. Prosight Management LP bought a new stake in Nabriva Therapeutics during the 4th quarter worth approximately $2,939,000. BlackRock Inc. grew its holdings in Nabriva Therapeutics by 154.0% during the 1st quarter. BlackRock Inc. now owns 453,064 shares of the biotechnology company’s stock worth $2,278,000 after acquiring an additional 274,709 shares during the last quarter. Renaissance Technologies LLC bought a new stake in Nabriva Therapeutics during the 4th quarter worth approximately $1,091,000. Finally, Dimensional Fund Advisors LP grew its holdings in Nabriva Therapeutics by 173.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 111,865 shares of the biotechnology company’s stock worth $563,000 after acquiring an additional 70,917 shares during the last quarter. 68.88% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Nabriva Therapeutics opened at $4.43 on Monday, MarketBeat Ratings reports. The company has a market capitalization of $162.65 million, a PE ratio of -1.78 and a beta of 1.78. Nabriva Therapeutics has a 12 month low of $4.39 and a 12 month high of $14.10.

Nabriva Therapeutics (NASDAQ:NBRV) last issued its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.23. The company had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $1.27 million. Nabriva Therapeutics had a negative net margin of 600.34% and a negative return on equity of 79.30%. sell-side analysts predict that Nabriva Therapeutics will post -1.73 earnings per share for the current fiscal year.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Analyst Recommendations for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.